Emmes rolls out cloud eClinical platform; confirms Moderna COVID vax trial role

Emmes has launched a cloud version of its e-clinical technology as a standalone software product, citing smaller biotech developers as a key target market.

The Rockville, Maryland-based clinical research organization (CRO) rolled out the third generation of its Advantage eClinical platform at the Society for Clinical Trials (SCT) conferences in San Diego, describing it as a suite of data management applications covering everything from study design to EDC.

The technology – which also includes randomization, supply management and patient-reported outcomes software as well as monitoring, verification and specimen tracking systems – is available in combination with consultation services or as a standalone product.

Hemang Maniar, chief information officer at Emmes, suggested the technology would be ideal for smaller organizations looking to take products into trials.

“One of the challenges many smaller biotechs face in the market is they don’t have access to an integrated technology platform for their trials. Options are incredibly limited and expensive, and they are often inflexible and lack support. This is exactly what we have set out to address with our third-generation Advantage eClinical platform.”

Maniar also cited the system’s flexibility as another advantage, explaining “What we are also providing is tremendous flexibility, and the client can choose to build their modules alone or engage our experienced data teams to provide guidance.

The combination of an integrated system built by experienced clinicians, flexible support, and cost-effective scale is unique in the current marketplace.”

COVID-19

The cloud platform builds on Advantage eClinical’s history of supporting over 1,000 clinical trials, including several high-profile adaptive COVID-19 trials.

Shortly after announcing the launch Emmes confirmed it will be supporting trials of Moderna mRNA COVID-19 vaccine at more than 50 sites in South and East Africa.

According to Emmes the clinical trial, which will include about 15,600 participants, seeks to better understand infection and disease in immunocompromised populations in order to prevent severe COVID-19 and chronic SARS-CoV-2 infections and minimize the risk of transmission.

It will also address the COVID-19 mRNA vaccine’s resistance to the variants that have been detected in South Africa and surrounding countries.

Image: Stock Photo Secrets